Literature DB >> 16137195

Microsatellite polymorphisms in DNA repair genes XRCC1, XRCC3 and XRCC5 in patients with gynecological tumors: association with late clinical radiosensitivity and cancer incidence.

K De Ruyck1, C S Wilding, M Van Eijkeren, R Morthier, E J Tawn, H Thierens.   

Abstract

This study investigates the association of microsatellite polymorphisms in XRCC1, XRCC3 and XRCC5 with the development of late radiation-induced radiotherapy reactions and examines the correlation between these microsatellites and cancer incidence. Sixty-two women with cervical or endometrial cancer treated with radiotherapy were included in the study. According to the CTCAEv3.0 scale, 22 patients showed late adverse radiotherapy reactions (grade 2 or more). PCR on lymphocyte DNA followed by automated fragment analysis was performed to examine the number of tandem repeat units at each locus. No significant association was found between the repeat length at any of the microsatellites in XRCC1, XRCC3 or XRCC5 and the incidence of late radiotherapy complications. Since higher odds ratios (ORs) were found for the rare XRCC1 [AC]11 and [AC]21 repeats (OR = 2.65, P = 0.325 and OR = 8.67, P = 0.093, respectively), the possible involvement of these small and large repeats in clinical radiosensitivity cannot be completely ruled out. When specific numbers of repeats were examined, no significant correlation was found between the microsatellite repeat length in XRCC1 and XRCC5 and cancer incidence. A weak correlation between XRCC3 [AC]16 homozygotes and cancer incidence was found (OR = 2.56, P = 0.055). A large-scale multicenter study of cancer patients with a high number of radiosensitive individuals is needed to clarify the value of rare polymorphic microsatellite repeats in XRCC1 and XRCC3 as a biomarker of clinical radiosensitivity or increased cancer risk.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16137195     DOI: 10.1667/rr3417.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  6 in total

1.  XRCC1 polymorphisms and cervical cancer risk: an updated meta-analysis.

Authors:  Jie Mei; Hai-Xia Duan; Ling-Ling Wang; Sen Yang; Jie-Qiang Lu; Ting-Yan Shi; Yu Zhao
Journal:  Tumour Biol       Date:  2013-09-21

Review 2.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

Review 3.  Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.

Authors:  Lucy Gossage; Srinivasan Madhusudan
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

4.  Genetics and genomics of radiotherapy toxicity: towards prediction.

Authors:  Catharine M West; Gillian C Barnett
Journal:  Genome Med       Date:  2011-08-23       Impact factor: 11.117

5.  A bioinformatics filtering strategy for identifying radiation response biomarker candidates.

Authors:  Jung Hun Oh; Harry P Wong; Xiaowei Wang; Joseph O Deasy
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

6.  DNA Repair Gene (XPD, XRCC4, and XRCC1) Polymorphisms in Patients with Endometrial Hyperplasia: A Pilot Study.

Authors:  Ebru Öztürk; Sacide Pehlivan; Ozcan Balat; Mete Gurol Ugur; Huseyin Caglayan Ozcan; Suna Erkılıç
Journal:  Med Sci Monit Basic Res       Date:  2018-10-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.